Yonsei University
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1885-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.yonsei.ac.kr
Refeeding in Post-ERCP Pancreatitis
Not Applicable
Recruiting
- Conditions
- Post-ERCP Pancreatitis
- Interventions
- Other: early refeedingOther: delayed refeeding
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 80
- Registration Number
- NCT04750044
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan-si, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Kyungpook National University School of Medicine, Daegu, Korea, Republic of
Cost-Effectiveness of Spyglass Direct Visualization System Facilitated Management for the Patients With Intrahepatic Bile Duct Stone and/or Large Extrahepatic Bile Duct Stone
Not Applicable
- Conditions
- Patients With Large or Impacted Intra- or Extra-hepatic Bile Duct Stone
- Interventions
- Device: ERCP using SpyGlass™ DS Direct Visualization SystemOther: PTCS
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 20
- Registration Number
- NCT04743089
- Locations
- 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of
Development of a Genome-based Platform for Personalized Treatment in Locally Advanced Rectal Cancer Patients
Not yet recruiting
- Conditions
- Locally Advanced Rectal Cancer
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 39
- Registration Number
- NCT04738214
- Locations
- 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of
Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Phase 2
- Conditions
- Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
- Interventions
- Drug: Niraparib-Bevacizumab
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 44
- Registration Number
- NCT04734665
- Locations
- 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of
Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy
Phase 2
Completed
- Conditions
- HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
- Interventions
- Drug: HERZUMA+mFOLFOX
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 36
- Registration Number
- NCT04722133
- Locations
- 🇰🇷
Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine, Seoul, Korea, Republic of
Effect of Smartphone Based Telemedicine and Education in Patients With Type 1 Diabetes Mellitus
Not Applicable
- Conditions
- Type 1 Diabetes Mellitus
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 100
- Registration Number
- NCT04721509
- Locations
- 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of
CONNECT DES Registrty
- Conditions
- Stent ThrombosisIschemic Heart DiseaseCoronary Artery DiseaseStent StenosisMyocardial Infarction
- Interventions
- Device: 1st-generation drug-eluting stentDevice: 2nd-generation drug-eluting stents
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 350000
- Registration Number
- NCT04715594
- Locations
- 🇰🇷
Hong Myeong-Ki, Seoul, Korea, Republic of
Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
Not Applicable
Recruiting
- Conditions
- Chronic Kidney Diseases
- Interventions
- Drug: dual anti-platelet therapy at least 6 monthsDrug: dual anti-platelet therapy 3months or less
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 900
- Registration Number
- NCT04708587
- Locations
- 🇰🇷
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy
- Conditions
- Lung MetastasesColorectal Cancer
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 400
- Registration Number
- NCT04704960
- Locations
- 🇰🇷
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Population Pharmacokinetics of Vancomycin, Meropenem, Milrinone, Dexmedetomidine and Fentanyl in Pediatric Patients During Extracorporeal Membrane Oxygenation
- Conditions
- Pediatric Patients Receiving Venoarterial Extracorporeal Membrane Oxygenation
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 50
- Registration Number
- NCT04701099
- Locations
- 🇰🇷
Department of Thoracic and Cardiovascular Surgery, Yonsei University Health System, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath